ECE2014 Poster Presentations Cardiovascular Endocrinology & Lipid Metabolism (41 abstracts)
Serum homocysteine levels are decreased in levothyroxine-treated women with autoimmune thyroiditis
Maciej Owecki 1 , Jolanta Dorszewska 2 , Nadia Sawicka-Gutaj 1 , Anna Oczkowska 2 , Michał K Owecki 2 , Michał Michalak 3 , Jakub Fischbach 1 , Wojciech Kozubski 2 & Marek Ruchała 1
1Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland; 2Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland; 3Department of Informatics and Statistics, Poznan University of Medical Sciences, Poznan, Poland.
Introduction: Some studies suggest that thyroid autoimmunity might be associated with increased cardiovascular-risk. However, the exact pathophysiology of this relationship has not yet been fully understood. In this study we aimed to analyze the influence of the levothyroixine (L-T4) replacement therapy and of anti-thyroperoxidase antibodies (TPOAbs) on homocysteine (Hcy) levels in patients with thyroid autoimmune disease.
Methods: 31 euthyroid women with Hashimoto is thyroiditis (HT) treated with L-T4 and 26 euthyroid women with positive TPOAbs, non-treated with L-T4 (non-treated HT) were enrolled to this case–control study. 40 healthy women matched for age and BMI served as controls. Exclusion criteria included: a history of any acute or chronic disease, such as diabetes mellitus, hypertension, angina pectoris, evidence of any kidney or liver disorder, use of any medications (including oral contraceptives and vitamin supplements), smoking, alcoholism.
Results: TPOAbs titers were significantly higher in both groups of patients with thyroid autoimmune disease (treated and non-treated HT) in comparison to healthy controls. Hcy levels were significantly lower in treated HT patients (Me 11 μmol; IQR 4.2 μmol) as compared with healthy controls (Me 13.35 μmol; IQR 6.34 μmol; P=0.0179). In contrast, there was no difference in Hcy levels between non treated HT and control group in Hcy. Levels of TSH, FT4, TC, LDL, HDL, and TAG did not differ between the study groups and the control group.
Conclusion: LT-4 replacement therapy is associated with a decrease of Hcy levels in patients with HT.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more